Back
SCYNEXIS, Inc. 10K Form
Sell
26
SCYX
SCYNEXIS, Inc.
Last Price:
$0.62
Seasonality Move:
-4.6%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-05-08 | 10Q | SCYX/SCYNEXIS, Inc. Quarterly |
| 2023-11-13 | 10Q | SCYX/SCYNEXIS, Inc. Quarterly |
| 2023-08-14 | 10Q | SCYX/SCYNEXIS, Inc. Quarterly |
| 2023-05-10 | 10Q | SCYX/SCYNEXIS, Inc. Quarterly |
| 2022-11-09 | 10Q | SCYX/SCYNEXIS, Inc. Quarterly |
| 2022-08-15 | 10Q | SCYX/SCYNEXIS, Inc. Quarterly |
Receive SCYX News And Ratings
See the #1 stock for the next 7 days that we like better than SCYX
SCYX Financial Statistics
Sales & Book Value
| Annual Sales: | $3.7M |
|---|---|
| Cash Flow: | $-8.7M |
| Price / Cash Flow: | 1.11 |
| Annual Sales: | $0.87 |
| Price / Book: | 0.72 |
Profitability
| EPS (TTM): | -0.53630 |
|---|---|
| Net Income (TTM): | $-25.3M |
| Gross Margin: | $0 |
| Return on Equity: | -51.63% |
| Return on Assets: | -34.25% |
SCYNEXIS, Inc. Earnings Forecast
Key SCYNEXIS, Inc. Financial Ratios
-
The Gross Profit Margin over the past 13 years for SCYX is 0.00%.
-
The Selling, General & Administrative Expenses for SCYX have been equal to 385.96% of Gross Profit Margin.
-
The Research & Development expenses have been 704.89% of Revenue.
-
The Net Earning history of SCYX is -568.29% of Total Revenues.
-
Per Share Earnings over the last 13 years have been positive in 8 years.
SCYNEXIS, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Pharmaceuticals |
| Sector: | Health Care |
| Current Symbol: | SCYX |
| CUSIP: | 811292 |
| Website: | scynexis.com |
Debt
| Debt-to-Equity Ratio: | 0.06 |
|---|---|
| Current Ratio: | 5.75 |
| Quick Ratio: | 4.49 |
Price-to-Earnings
| Trailing P/E Ratio: | 0.66 |
|---|---|
| Forward P/E Ratio: | 11.29 |
SCYX Technical Analysis vs Fundamental Analysis
Sell
26
SCYNEXIS, Inc. (SCYX)
is a Sell
Is SCYNEXIS, Inc. a Buy or a Sell?
-
SCYNEXIS, Inc. stock is rated a SellThe current SCYNEXIS, Inc. [SCYX] share price is $0.63. The Score for SCYX is 26, which is 48% below its historic median score of 50, and infers higher risk than normal.